Compare Crispr Therapeutics AG (CRSP) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Crispr Therapeutics AG trades at $54.31 (market cap $5.17B), while First Trust NASDAQ 100 Technology Index Fund trades at $315.63. The key difference: First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | QTEC | |
|---|---|---|
Market Cap | $5.17B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $76.78 | $335.74 |
52-Week Low | $44.34 | $207.03 |
Enterprise Value | $3.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.52, up 3.64% in the last session, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by Casgevy sales. Analyst consensus is a Buy with a $76 price target, reflecting optimism for pipeline catalysts.
The outlook is supported by strong product sales and clinical progress, but significant risks include persistent negative margins, high cash burn, and reliance on pipeline success. Investors face a high-risk, high-reward scenario with the stock trading near resistance levels amid volatile earnings history.
QTEC trades at $316.59, up 1.7% with a bullish technical signal from moving averages. The ETF, tracking NASDAQ-100 technology stocks, lacks disclosed P/E and P/S ratios. A small dividend of $0.03 is scheduled for June 2026, with support at $313 and resistance at $319.
Outlook remains positive due to strong technical momentum, though overbought RSI signals caution. Risks include tech sector volatility and reliance on broad market trends. Analyst coverage highlights its role for diversified tech exposure without specific ratings available.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
